Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

Inclusion Criteria:

• Patients over 50 years of age diagnosed with wet age-related macular degenerationhaving indication of antiangiogenic therapy.
• Both genders.
• Subjects able to give informed consent.

Exclusion Criteria:

• Patients with contraindication to receive bevacizumab:
• Hypersensitivity to the active ingredient or to some of the formula excipients.
• Hypersensitivity to products derived from CHO cells or to other human recombinantantibodies or humanized antibodies.
• Patients having received intravitreal antiangiogenic therapy prior to wet AMDtreatment.
• Patients receiving previous systemic antiangiogenic therapy.
• Wet AMD in the healing period or disciform scar.
• Pregnant, breastfeeding or childbearing-aged women.
• Any person with choroidal neovascularization not associated to wet AMD.
• History of retinal or intraocular surgery in the affected eye in the last threemonths.
• Vitrectomy in the affected eye.
• Any significant ocular infection, active or suspected, having compromised or able tocompromise the eye to be studied.
• Ocular inflammatory disease.
• Myopia exceeding -8 diopters.
• Extensive subfoveal subretinal hemorrhage > 2 papillary diameter (PD).
• Coexistence of other severe ocular diseases: uncontrolled ocular hypertension,terminal glaucoma, diabetic retinopathy, retinal vein thrombosis, optic atrophy.
• History of stroke or myocardial infarction in the last 6 months.
• Patients with coagulopathies.
• Patients physically or mentally disabled to participate in such visual tests.